Bayer's Plischke sees likely slowdown in blood loss drug Trasylol sales growth

Bayer's Plischke sees likely slowdown in blood loss drug Trasylol sales growth: "Bayer AG can expect a slowdown in the growth in sales of its blood loss drug Trasylol, after an independent study showed that the drug was associated with health risks, board member Wolfgang Plischke said after the full-year results news conference." [Forbes]